Abstract
The 5-HT3 receptor is a member of the Cys-loop family of ligand-gated ion channels. These receptors are located in both the peripheral and central nervous systems, where functional receptors are constructed from five subunits. These subunits may be the same (homopentameric 5-HT3A receptors) or different (heteropentameric receptors, usually comprising of 5-HT3A and 5-HT3B receptor subunits), with the latter having a number of distinct properties. The 5-HT3 receptor binding site is comprised of six loops from two adjacent subunits, and critical ligand binding amino acids in these loops have been largely identified. There are a range of selective agonists and antagonists for these receptors and the pharmacophore is reasonably well understood. There are also a wide range of compounds that can modulate receptor activity. Studies have suggested many diverse potential disease targets that might be amenable to alleviation by 5-HT3 receptor selective compounds but to date only two applications have been fully realised in the clinic: the treatment of emesis and irritable-bowel syndrome.
Keywords: Serotonin receptor, ligand-gated ion channel, 5-HT3 receptor, ligand binding, antagonist, agonist, pharmacology, disease
Current Pharmaceutical Design
Title: 5-HT3 Receptors
Volume: 12 Issue: 28
Author(s): A. J. Thompson and S. C. R. Lummis
Affiliation:
Keywords: Serotonin receptor, ligand-gated ion channel, 5-HT3 receptor, ligand binding, antagonist, agonist, pharmacology, disease
Abstract: The 5-HT3 receptor is a member of the Cys-loop family of ligand-gated ion channels. These receptors are located in both the peripheral and central nervous systems, where functional receptors are constructed from five subunits. These subunits may be the same (homopentameric 5-HT3A receptors) or different (heteropentameric receptors, usually comprising of 5-HT3A and 5-HT3B receptor subunits), with the latter having a number of distinct properties. The 5-HT3 receptor binding site is comprised of six loops from two adjacent subunits, and critical ligand binding amino acids in these loops have been largely identified. There are a range of selective agonists and antagonists for these receptors and the pharmacophore is reasonably well understood. There are also a wide range of compounds that can modulate receptor activity. Studies have suggested many diverse potential disease targets that might be amenable to alleviation by 5-HT3 receptor selective compounds but to date only two applications have been fully realised in the clinic: the treatment of emesis and irritable-bowel syndrome.
Export Options
About this article
Cite this article as:
Thompson J. A. and R. Lummis C. S., 5-HT3 Receptors, Current Pharmaceutical Design 2006; 12 (28) . https://dx.doi.org/10.2174/138161206778522029
DOI https://dx.doi.org/10.2174/138161206778522029 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 4
Current Genomics Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Medicinal Chemistry Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Early Genetic Changes Involved in Low-Grade Astrocytic Tumor Development
Current Molecular Medicine Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics ExomiRs: A Novel Strategy in Cancer Diagnosis and Therapy
Current Gene Therapy IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine A Novel µ-Opioid Receptor Ligand with High In Vitro and In Vivo Agonist Efficacy
Current Medicinal Chemistry Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer
Current Genomics Direct Conversion of Dermal Fibroblasts into Neural Progenitor Cells by a Novel Cocktail of Defined Factors
Current Molecular Medicine Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry